A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs MCS 110 (Primary) ; Carboplatin; Gemcitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 04 Jul 2017 This trial has been suspended in Austria as per European Clinical Trials Database record.
- 30 Jun 2017 Planned End Date changed from 7 Apr 2019 to 6 Oct 2019.
- 28 Jun 2017 This trial has been suspended in Germany.